Drugs / FXS0683
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07616089 | Jun 2026 → Aug 2028 expected | B-cell neoplasm, acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FXS0683 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07616089 ↗ |
| Action | Inhibit | “FXS0683 is a potent and highly selective BCL-2 inhibitor” NCT07616089 ↗ |
| Route | Oral | “FXS0683 will be administered orally once daily at assigned dose levels in 28-day cycles.” NCT07616089 ↗ |
| Target | BCL2 | “FXS0683 is a potent and highly selective BCL-2 inhibitor” NCT07616089 ↗ |